Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of Opdivo and Yervoy, this time in newly diagnosed liver cancer. PD-1 inhibitor ...

With so many exciting sporting events happening year-round, it can be tough to know where to stream each one. Thankfully, Fubo should have all your bases covered, no pun intended. Fubo is a live TV ...

Gilead and Arcus’ efforts to rebuild confidence in TIGIT as a drug target for cancer immunotherapies have shuffled forwards again, with new data showing signs of efficacy in a combination regimen used ...